Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics.

relatlimab (BMS-986016) - BMS

PTRY - Chiome Biosci

Tecentriq (atezolizumab) - Roche

Keytruda (pembrolizumab) - Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/39929828

Asami Yoshioka; Claudia De Lorenzo; Kentaro Kajiwara; Koji Nakamura; Lorenzo Manna; Margherita Passariello; Rosa Rapuano Lembo; Shu-Ichi Hashimoto; Toshikazu Inoue

Feb 11, 2025